CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 25 enrolled
Drug / intervention
CAD-1883drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03688685
NCT03688685Phase 2Completed
CompareCT.gov

A Phase 2a Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of CAD-1883 Oral Treatment in Adults With Essential Tremor

Cadent Therapeutics·interventional·Posted Sep 28, 2018·Updated Aug 5, 2021

In Brief

A Phase 2 clinical trial evaluating CAD-1883 for Essential Tremor. Completed, enrolled 25 participants across 7 sites.

Detailed Summary

This is an open-label study designed to evaluate the safety, tolerability and efficacy of CAD-1883, a positive allosteric modulator of the SK channel, administered twice daily orally to adult patients with ET. Patients with the diagnosis of ET based on the Movement Disorder Society (MDS) criteria with a documented severity of tremor based on the clinician-administered TETRAS Performance Subscale are eligible to be enrolled in the study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEssential Tremor
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedSep 28, 2018
Enrollment StartJan 23, 2019
Primary CompletionSep 10, 2019
Study CompletionSep 24, 2019
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 7.8 years ago

Interventions

CAD-1883drug

Treatment groups receiving twice-daily oral dosing of CAD-1883 for a treatment period of 14 days.